{"id":"hum0280","version":1,"url":"https://humandbs.dbcls.jp/research/hum0280/v1","datePublished":"2022-01-07","versions":[{"version":1,"datePublished":"2022-01-07"}],"title":{"ja":"肺癌患者における標的抗原の同定とがん微小環境の解析","en":"The research for the identification of neoantigen and tumor immune microenvironment in lung cancer"},"summary":{"aims":{"ja":"肺がんにおける患者毎の標的抗原とがん微小環境を明らかにし、それに基づいた最適な複合的免疫療法を開発すること。","en":"To evaluate the tumor immune microenvironment (TIME) of lung cancer to develop a new immune based therapy."},"methods":{"ja":"RNA-seq解析データから、Molecular Signatures Database（MSigDB）の遺伝子セットに基づきsingle sample Gene Set Enrichment analysis（ssGSEA）を行い、腫瘍（T-score: Glycolysis, Mitotic spindle）、宿主免疫応答（I-score: T cells, B cells, MHC-complex）、免疫応答抑制（S-score: angiogenesis, hypoxia, epithelial mesenchymal transition, cytokine production suppression）の3因子に分類し、スコアを算出した。","en":"We carried out RNA sequencing (RNA-seq) on 113 tumor tissues from patients with lung cancer. To evaluate the tumor immune microenviroment (TIME), we calculated the score (T-score; Glycolysis, Mitotic spindle, I-score; T cells, B cells, MHC-complex, S-score; angiogenesis, hypoxia, epithelial mesenchymal transition, cytokine production suppression) using single sample Gene Set Enrichment Analysis (ssGSEA)."},"targets":{"ja":"2019年8月から2020年6月の間に根治切除を行った原発性肺がん症例の内、新鮮腫瘍検体が採取できた113症例。","en":"We enrolled a total of 113 patients with lung cancer who underwent lung resection from August 2019 to June 2021 and obtained the fresh tumor samples."},"url":{"ja":null,"en":null}},"listingSummary":{"methods":{"ja":"発現","en":"Expression profiling"},"targets":{"ja":"肺癌：113症例\n（日本人）","en":"lung cancer: 113 cases\n(Japanese)"},"typeOfData":{"ja":"NGS\n（RNA-seq）","en":"NGS\n(RNA-seq)"}},"releaseNote":{"ja":"原発肺がん113症例の腫瘍組織より抽出したRNAを用いたRNA sequencing解析の結果をfastqファイルにて提供する。","en":"RNAs extracted from tumor tissues of 113 lung cancer patients were used for the RNA sequencing analysis. Fastq files are provided."},"dataProviders":[{"name":{"ja":"松下 博和","en":"Hirokazu Matsushita"},"organization":{"name":{"ja":"愛知県がんセンター 腫瘍免疫制御TR分野","en":"Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute"}}}],"researchProjects":[{"name":{"ja":"肺癌患者における標的抗原の同定とがん微小環境の解析","en":"Identification of target antigens and analysis of cancer microenvironments in lung cancer patients"},"url":{"ja":null,"en":null}}],"grants":[{"title":{"ja":"末梢血中循環腫瘍細胞を用いた非小細胞肺癌への化学療法による免疫原性細胞死の解析","en":"Investigation of Immunogenic cell death related to chemotherapy in circulating tumor cells"},"agency":{"ja":"科学研究費助成事業 基盤研究（C）","en":"KAKENHI Grant-in-Aid for Scientific Research (C)"},"grantIds":["20K09187"]},{"title":{"ja":"肺がん長期生存症例のネオアンチゲンに対する免疫応答の検討","en":"Specific immune responses against tumor antigens in long term survivors of cancer"},"agency":{"ja":"科学研究費助成事業 基盤研究（B）","en":"KAKENHI Grant-in-Aid for Scientific Research (B)"},"grantIds":["19H03528"]},{"title":{"ja":"肺癌免疫療法における細胞傷害性CD4陽性T細胞に関する探索的研究：新たな免疫療法治療ターゲットの可能性","en":"The identification of CD4 positive cytotoxic T cell as a new target for immune-based therapy"},"agency":{"ja":"呼吸器財団","en":"Japanese Respiratory Foundation"},"grantIds":null}],"relatedPublications":[],"datasets":["DRA012560"],"controlledAccessUsers":[]}